Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485433 | 0.79 | HTR2C (0.50) | CACNA1BHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3485825 | 0.77 | CACNA1B (0.55) | CACNA1B | |
| SCHEMBL3486045 | 0.77 | HTR2C (0.51) | CACNA1BHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3485485 | 0.77 | HTR2C (0.50) | HTR6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL532533 | 0.75 | KDM4E (0.46) | HTR6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4279499 | 0.72 | CACNA1B (0.47) | CACNA1BRORC | |
| SCHEMBL4277650 | 0.72 | CACNA1B (0.47) | CACNA1BRORC | |
| SCHEMBL3561054 | 0.70 | HTR2C (0.46) | HTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL617654 | 0.68 | HTR6 (0.66) | HTR6SLC6A4DRD2 | |
| SCHEMBL1134333 | 0.68 | TSHR (0.47) | HTR6KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885RORC 3919/4885HTR6 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.